The new laboratories occupy a surface area of 1,300 square metres, which the scientists based there will use to develop drugs. “We chose Basel for Lonza’s first-ever drug product development facility because it offers us access to the latest technologies and world-leading experts in a central location, one that’s a hub of innovation in the pharma industry,” explained Richard Ridinger, CEO of Lonza, in a statement.
The laboratories in the Stücki Science Park will focus initially on formulation and analytical development, as well as quality control. “The new state-of-the-art facility can support not just global, established pharma customers, but also small startups like the ones that make their home in Basel,” commented Christoph Brutschin, state councillor, head of the Department of Economic, Social and Environmental Affairs of the canton of Basel-Stadt and president of the Conference of the Cantonal Councillors for the Economy (CCCE). During the opening ceremony, he was one of 75 guests and employees given a tour around the new facilities.